Marion Dorsch
President at Atavistik Bio, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Kaye Foster-Cheek | F | 64 | 10 years | |
| May Kin Ho | M | 71 | 9 years | |
| Bryan Stuart | M | 47 |
Atavistik Bio, Inc.
 Atavistik Bio, Inc. BiotechnologyHealth Technology Atavistik Bio, Inc. is a pre-clinical stage biotechnology company located in an undisclosed location. The American company is pioneering a synthetic, scalable approach to identify and harness highly conserved protein-metabolite interactions to revolutionize small molecule drug discovery. The company's advanced data analytics and AI platforms leverage structure-based drug design to engineer novel, highly specific small molecule drugs to activate, inhibit or stabilize targets. The company is led by an experienced management team and advisors, plus a robust investment syndicate, and is positioned to deliver transformational science to ultimately improve patient care. Atavistik Bio was founded by prominent scientists who are considered among the leading authorities in cell biology, cancer cell biology and cell metabolism. Bryan E Stuart has been the CEO of the company since 2023. | 1 years |
| Christina Rossi | F | 48 | 6 years | |
| Becker Hewes | M | 58 | 4 years | |
| Jim Burns | M | 46 | 8 years | |
| Helen Hobbs | M | 71 |
Atavistik Bio, Inc.
Atavistik Bio, Inc. BiotechnologyHealth Technology Atavistik Bio, Inc. is a pre-clinical stage biotechnology company located in an undisclosed location. The American company is pioneering a synthetic, scalable approach to identify and harness highly conserved protein-metabolite interactions to revolutionize small molecule drug discovery. The company's advanced data analytics and AI platforms leverage structure-based drug design to engineer novel, highly specific small molecule drugs to activate, inhibit or stabilize targets. The company is led by an experienced management team and advisors, plus a robust investment syndicate, and is positioned to deliver transformational science to ultimately improve patient care. Atavistik Bio was founded by prominent scientists who are considered among the leading authorities in cell biology, cancer cell biology and cell metabolism. Bryan E Stuart has been the CEO of the company since 2023. | - |
| John Josey | M | 63 |
Atavistik Bio, Inc.
Atavistik Bio, Inc. BiotechnologyHealth Technology Atavistik Bio, Inc. is a pre-clinical stage biotechnology company located in an undisclosed location. The American company is pioneering a synthetic, scalable approach to identify and harness highly conserved protein-metabolite interactions to revolutionize small molecule drug discovery. The company's advanced data analytics and AI platforms leverage structure-based drug design to engineer novel, highly specific small molecule drugs to activate, inhibit or stabilize targets. The company is led by an experienced management team and advisors, plus a robust investment syndicate, and is positioned to deliver transformational science to ultimately improve patient care. Atavistik Bio was founded by prominent scientists who are considered among the leading authorities in cell biology, cancer cell biology and cell metabolism. Bryan E Stuart has been the CEO of the company since 2023. | 2 years |
| Fouad Namouni | M | 55 | 4 years | |
| Adam Goulburn | M | 42 |
Atavistik Bio, Inc.
Atavistik Bio, Inc. BiotechnologyHealth Technology Atavistik Bio, Inc. is a pre-clinical stage biotechnology company located in an undisclosed location. The American company is pioneering a synthetic, scalable approach to identify and harness highly conserved protein-metabolite interactions to revolutionize small molecule drug discovery. The company's advanced data analytics and AI platforms leverage structure-based drug design to engineer novel, highly specific small molecule drugs to activate, inhibit or stabilize targets. The company is led by an experienced management team and advisors, plus a robust investment syndicate, and is positioned to deliver transformational science to ultimately improve patient care. Atavistik Bio was founded by prominent scientists who are considered among the leading authorities in cell biology, cancer cell biology and cell metabolism. Bryan E Stuart has been the CEO of the company since 2023. | - |
| Christopher Murray | M | 61 | 7 years | |
| Janet Loesberg | M | 61 | 4 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Kevin Starr | M | 61 | 7 years | |
| Marc Tessier-Lavigne | M | 64 | 5 years | |
| Eric Schweitzer | M | 58 |
Freie Universität Berlin
| 6 years |
| Perry Karsen | M | 69 | 5 years | |
| Megan E. Pace | F | 51 | - | |
| Darrin Miles | M | - | 6 years | |
| Hans-Georg Frank | M | 63 |
Freie Universität Berlin
| 7 years |
| Glenn Goddard | M | 53 | 6 years | |
| Paul Clancy | M | 62 | 10 years | |
| J. Goater | M | 48 |
Atavistik Bio, Inc.
Atavistik Bio, Inc. BiotechnologyHealth Technology Atavistik Bio, Inc. is a pre-clinical stage biotechnology company located in an undisclosed location. The American company is pioneering a synthetic, scalable approach to identify and harness highly conserved protein-metabolite interactions to revolutionize small molecule drug discovery. The company's advanced data analytics and AI platforms leverage structure-based drug design to engineer novel, highly specific small molecule drugs to activate, inhibit or stabilize targets. The company is led by an experienced management team and advisors, plus a robust investment syndicate, and is positioned to deliver transformational science to ultimately improve patient care. Atavistik Bio was founded by prominent scientists who are considered among the leading authorities in cell biology, cancer cell biology and cell metabolism. Bryan E Stuart has been the CEO of the company since 2023. | 2 years |
| Frank Czichowski | M | 64 |
Freie Universität Berlin
| 10 years |
| Jacqueline Cinicola | F | - | 7 years | |
| Sacha Fabian Berlik | M | 54 |
Freie Universität Berlin
| 5 years |
| Kristian Schmidt-Garve | M | 53 |
Freie Universität Berlin
| 5 years |
| Robert Sheroff | M | 69 | 2 years | |
| Quaza Nizamuddin bin A. Hassan Nizam | M | 64 |
Freie Universität Berlin
| 1 years |
| Nikolas von Haugwitz | M | 56 |
Freie Universität Berlin
| 4 years |
| Melissa McLaughlin | F | - | 7 years | |
| Renee T. Leck | F | - | 3 years | |
| Ann Barbier | M | 59 | 2 years | |
| Dorte Hoppner | M | - |
Freie Universität Berlin
| 4 years |
| Christopher Turner | M | 56 | 3 years | |
| Caroline Knöri | F | 49 |
Freie Universität Berlin
| 4 years |
| Kevin Marks | M | - | 2 years | |
| Eyal Attar | M | 53 | 5 years | |
| Petra Wierzchowski | F | 58 |
Freie Universität Berlin
| 4 years |
| Camille Henderson | M | - | 4 years | |
| Constanze Ulmer-Eilfort | M | 62 |
Freie Universität Berlin
| 3 years |
| Richa Poddar | F | - | 6 years | |
| Robert J. DeVita | M | - | - | |
| Hanns-Alexander Klemm | M | - |
Freie Universität Berlin
| 3 years |
| Pamela Knapp | F | 66 |
Freie Universität Berlin
| 4 years |
| Bernd Buchholz | M | 62 |
Freie Universität Berlin
| 4 years |
| Henrik Colell | M | 60 |
Freie Universität Berlin
| 4 years |
| Marion Helmes | M | 58 |
Freie Universität Berlin
| 4 years |
| John Duncan Higgons | M | 69 | 7 years | |
| Frank Conarad | M | 62 |
Freie Universität Berlin
| 4 years |
| Torsten Leue | M | 57 |
Freie Universität Berlin
| 4 years |
| Arndt Rolfs | M | 64 |
Freie Universität Berlin
| 4 years |
| Niko Stumpfögger | M | 68 |
Freie Universität Berlin
| 2 years |
| Alojzy Zbigniew Nowak | M | - |
Freie Universität Berlin
| 4 years |
| Christine Wolff | F | 63 |
Freie Universität Berlin
| 1 years |
| Stefan Herm | M | - |
Freie Universität Berlin
| 5 years |
| Andrew Hirsch | M | 53 | 4 years | |
| Martin Auer | M | 64 |
Freie Universität Berlin
| 3 years |
| Matthias Lindenberger | M | 57 |
Freie Universität Berlin
| - |
| Christoph S. Lengauer | M | 59 | 4 years | |
| Jörg Lübcke | M | 58 |
Freie Universität Berlin
| 4 years |
| Karl-Ludwig Soll | M | - |
Freie Universität Berlin
| 4 years |
| Christopher Bowden | M | 63 | 7 years | |
| Meredith Goldwasser | M | 52 | 6 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 36 | 57.14% |
| Germany | 27 | 42.86% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Marion Dorsch
- Personal Network
